Pipeline

Advancing drug candidates with the goal of delivering transformative medicines for patients

Our ReSOLVE™ platform enables a highly differentiated pipeline of small molecule therapeutics for highly validated innate immunity targets. Our lead programs target the inflammasome and nucleic acid sensing pathways. We have multiple programs in discovery and are pursuing a broad pipeline of additional targets.

Pipeline

ProgramDiscoveryLead OptimizationIND-EnablingPhase 1
cGAS Franchise
VENT-03

Immunology, Inflammation, Dermatology

Brain-Penetrant

Neuroinflammation, Neurodegeneration

Topical
Next-Gen Systemic
NLRP3 Franchise
VENT-02

Neuroinflammation, Neurodegeneration

Wholly Owned Systemic

Inflammation, Pulmonology

VENT-01

Nephrology, Cardiology, Hepatology

novo nordisk
Undisclosed
Brain-Penetrant

Neuroinflammation, Neurodegeneration

Systemic

Immunology, Gastroenterology

Additional Discovery Programs

We have multiple programs in discovery and are pursuing a broad pipeline of additional targets

cGAS Franchise
VENT-03
Immunology, Inflammation, Dermatology
Phase 1
Brain-Penetrant
Neuroinflammation, Neurodegeneration
Lead Optimization
Topical
Lead Optimization
Next-Gen Systemic
Lead Optimization
NLRP3 Franchise
VENT-02
Neuroinflammation, Neurodegeneration
Phase 1
Wholly Owned Systemic
Inflammation, Pulmonology
Lead Optimization
VENT-01
Nephrology, Cardiology, Hepatology
IND-Enabling
novo nordisk
Undisclosed
Brain-Penetrant
Neuroinflammation, Neurodegeneration
Lead Optimization
Systemic
Immunology, Gastroenterology
Lead Optimization
Additional Discovery Programs

We have multiple programs in discovery and are pursuing a broad pipeline of additional targets